About Liber Pharmaceuticals
Liber began life as Nicovape in 2016 as an independent, Australian-owned and operated manufacturer of therapeutic vaping products to aid smoking cessation.
With the TGA’s announcement of the rescheduling of vaping products containing nicotine as Schedule 4 medicines, Nicovape was able to move its operations onshore and in December 2020, Liber Pharmaceuticals was established domestically in Australia to supply its high-quality Nicovape® Q therapeutic vapes to the pharmaceutical supply chain.
The change to Liber aligned with the emerging scientific consensus that nicotine-containing vapes could be considered as a therapeutic intervention for smoking cessation and management of nicotine dependence and can be manufactured to the standards required of pharmaceutical products – a concept that Liber has pioneered, and others have merely tried to follow.
Liber has consistently advocated for providing therapeutic vapes through pharmacy-only access, coupled with medical supervision. Access should be limited to those who would benefit from it, as a responsible and effective way to ensure that smokers, or those managing a nicotine addiction, receive the support they need when they attempt to quit. This approach also provides the surest safeguard to prevent access by youth and non-smokers.
Liber’s commitment to this approach has been validated by the TGA, which has assumed stewardship of nicotine-containing vapes for the Australian market by establishing a framework for therapeutic vaping products.
Likewise, Liber’s R&D program, which focuses on novel approaches to e-liquid safety, has been:
- Approved by AusIndustry for the federal government’s Research & Development Tax Incentive (RDTI) program, and
- Liber’s commercial approach has been approved by Austrade for the Export Market Development Grant (EMDG) program.
Liber has never been a ‘lifestyle’ vaping company. Our focus is on developing vaporiser technology as a means of administering medicines, with a primary emphasis on nicotine for smoking cessation or managing nicotine dependence.
Liber’s application of pharmaceutical standards to its products, our focus on product safety through novel R&D and our approach to medically supervised cessation are key tenets of our commitment to seeing the Nicovape® Q products achieve registration on the ARTG:
Pharmaceutical quality manufacturing standards
Liber’s Nicovape® Q is manufactured in line with standards expected of licensed medical devices:
- Our Nicovape® Q devices are manufactured in an ISO-13485 (medical devices) and GMP-certified facility
- Our manufacturing processes comply with ISO 14971 – risk management of medical devices
- Our Nicovape® Q liquids are developed in line with pharmaceutical drug development protocols
Quality ingredients and formulations
Liber’s nicotine is manufactured in Switzerland under pharmaceutical cGMP, and our flavour formulations are produced in a UK-based facility using US/EU Pharmacopoeia primary ingredients.
All flavouring ingredients have been molecularly defined and undergo toxicological risk assessment (TRA).
Medical supervision
Liber is the only company to have incorporated medical supervision and support from day one as an integral part of optimising the patient outcomes for those who access our products.
Liber’s products have not been marketed or sold as consumer goods, anywhere, ever.
Domestically insured
Liber holds full product liability insurance coverage for the Australasian region, as the national pharmaceutical supply chain requires.
Find your nearest stockist
Over 1,000 community pharmacies across Australia currently hold nicotine vaping products in-store.